Pharma News and Analysis cover art

Pharma News and Analysis

Pharma News and Analysis

Written by: AP
Listen for free

About this listen

 Welcome to Pharma News & Analysis, a premier Podcast dedicated to keeping you informed and engaged in the ever-evolving pharmaceutical landscape. Stay ahead of the curve with our insightful news coverage, deep-dive analyses, and expert perspectives on topics that matter most in the pharmaceutical industry.AP Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • Brain Gain: AbbVie's $8.7 Billion Bet on Cerevel

    Brain Gain: AbbVie's $8.7 Billion Bet on Cerevel
    Dec 8 2023

    This episode of the Pharma News and Analysis Podcast dives deep into the recent news of AbbVie's acquisition of Cerevel Pharma, a strategic move that marks the company's significant investment in the burgeoning field of neuroscience.

    Tune in to this captivating episode to gain a deeper understanding of this strategic move and its potential impact on the future of neuroscience.
    Show More Show Less
    3 mins
  • Roche's Multi-Billion Dollar Bet on Obesity

    Roche's Multi-Billion Dollar Bet on Obesity
    Dec 8 2023

    Can Carmot Crack the Obesity Code? Roche's Multi-Billion Dollar Bet

    Join us as we delve deeper into this exciting development and analyze its potential impact on the global obesity market.

    Tune in to this episode of the Pharma News and Analysis Podcast for an in-depth discussion on Roche's strategic move and its implications for the future of obesity treatment.
    Show More Show Less
    4 mins
  • Hope and Fear: A Balancing Act with CAR-T Therapy

    Hope and Fear: A Balancing Act with CAR-T Therapy
    Dec 8 2023

    In this episode we'll be focusing on a recent development with significant implications for the field of cancer treatment: CAR-T therapy.

    Details on the potential link between CAR-T cell therapy and the development of T-cell malignancies, including the specific type known as CAR-positive lymphoma. FDA actions and what to expect
    Show More Show Less
    3 mins
No reviews yet